The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators
Abstract
In the last decade, the discovery and cloning of the cyclin-dependent kinases (cdks), key regulators of cell cycle progression, have led to the identification of novel modulators of cdk activity. Initial experimental results demonstrated that these cdk modulators are able to block cell cycle progression, induce apoptotic cell death, promote differentiation, inhibit angiogenesis, and modulate transcription. Alteration of cdk activity may occur indirectly by affecting upstream pathways that regulate cdk activity or directly by targeting the cdk holoenzyme. Two direct cdk modulators, flavopiridol and UCN-01, are showing promising results in early clinical trials, in which the drugs reach plasma concentrations that can alter cdk activity in vitro. Although modulation of cdk activity is a well-grounded concept and new cdk modulators are being assessed for clinical testing, important scientific questions remain to be addressed. These questions include whether one or more cdks should be inhibited, how cdk inhibitors should be combined with other chemotherapy agents, and which cdk substrates should be used to assess the biologic effects of these drugs in patients. Thus, modulation of cdk activity is an attractive target for cancer chemotherapy, and several agents that modulate cdk activity are in or are approaching entry into clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
The regulation of E2F by pRB-family proteins.
Dyson, N. (1998) · Genes & Development · doi:10.1101/gad.12.15.2245 · Cited by 2,317
CYCLIN-DEPENDENT KINASES: Engines, Clocks, and Microprocessors
Morgan, D. O. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.261 · Cited by 2,259
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,477
New functional activities for the p21 family of CDK inhibitors.
LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., & Harlow, E. (1997) · Genes & Development · doi:10.1101/gad.11.7.847 · Cited by 1,402
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Wei, P., Garber, M. E., Fang, S.-M., Fischer, W. H., & Jones, K. A. (1998) · Cell · doi:10.1016/s0092-8674(00)80939-3 · Cited by 1,249
Cheng, M., Olivier, P., Diehl, J. A., Fero, M., Roussel, M. F., Roberts, J. M., & Sherr, C. J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1571 · Cited by 1,142
Graña, X., & Reddy, E. P. (1995) · PubMed · Cited by 1,139
Distinct Roles for Cyclin-Dependent Kinases in Cell Cycle Control
van den Heuvel, S., & Harlow, E. (1993) · Science · doi:10.1126/science.8266103 · Cited by 1,092
Paull, K. D., Shoemaker, R. H., Hodes, L., Monks, A., Scudiero, D. A., Rubinstein, L., Plowman, J., & Boyd, M. R. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.14.1088 · Cited by 967
Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors
Gray, N. S., Wodicka, L., Thunnissen, A.-M. W. H., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., et al. (1998) · Science · doi:10.1126/science.281.5376.533 · Cited by 808
De Azevedo, W. F., Leclerc, S., Meijer, L., Havlicek, L., Strnad, M., & Kim, S. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.0518a.x · Cited by 729
Niculescu, A. B., Chen, X., Smeets, M., Hengst, L., Prives, C., & Reed, S. I. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.629 · Cited by 724
Carlson, B. A., Dubay, M., Sausville, E. A., Brizuela, L., & Worland, P. J. (1996) · PubMed · Cited by 580
Identification of multiple cyclin subunits of human P-TEFb
Peng, J., Zhu, Y., Milton, J. T., & Price, D. H. (1998) · Genes & Development · doi:10.1101/gad.12.5.755 · Cited by 519
De Azevedo, W. F., Mueller-Dieckmann, H. J., Schulze-Gahmen, U., Worland, P. J., Sausville, E., & Kim, S. H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2735 · Cited by 496
Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2
Colas, P., Cohen, B., Jessen, T., Grishina, I., McCoy, J., & Brent, R. (1996) · Nature · doi:10.1038/380548a0 · Cited by 459
UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53
Wang, Q., Fan, S., Eastman, A., Worland, P. J., Sausville, E. A., & O'Connor, P. M. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.14.956 · Cited by 453
Self-citationLevkau, B., Koyama, H., Raines, E. W., Clurman, B. E., Herren, B., Orth, K., Roberts, J. M., & Ross, R. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80055-6 · Cited by 441
Senderowicz, A. M., Headlee, D., Stinson, S. F., Lush, R. M., Kalil, N., Villalba, L., Hill, K., Steinberg, S. M., Figg, W. D., Tompkins, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2986 · Cited by 403
Self-citationFredersdorf, S., Burns, J., Milne, A. M., Packham, G., Fallis, L., Gillett, C. E., Royds, J. A., Peston, D., Hall, P. A., Hanby, A. M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6380 · Cited by 357
Nuclear Accumulation of p21 Cip1 at the Onset of Mitosis: a Role at the G 2 /M-Phase Transition
Dulić, V., Stein, G. H., Far, D. F., & Reed, S. I. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.546 · Cited by 353
Michalides, R. J. A. M., van Veelen, N., Hart, A. A. M., Loftus, B. M., Wientjens, E., & Balm, A. J. M. (1995) · PubMed · Cited by 352
Zhang, H. S., Postigo, A. A., & Dean, D. C. (1999) · Cell · doi:10.1016/s0092-8674(00)80714-x · Cited by 349
Growth Inhibition With Reversible Cell Cycle Arrest of Carcinoma Cells by Flavone L86-8275
Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C., Czech, J., Naik, R., & Sausville, E. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.22.1736 · Cited by 346
Potent Inhibition of Cdc2 Kinase Activity by the Flavonoid L86-8275
Losiewicz, M. D., Carlson, B. A., Kaur, G., Sausville, E. A., & Worland, P. J. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1742 · Cited by 345
Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27.
Katayose, Y., Kim, M., Rakkar, A. N. S., Li, Z., Cowan, K. H., & Seth, P. K. (1997) · PubMed · Cited by 344
Hashemolhosseini, S., Nagamine, Y., Morley, S. J., Desrivières, S., Mercep, L., & Ferrari, S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14424 · Cited by 342
[28] Use and specificity of staurosporine, UCN-O1, and calphostin C as protein kinase inhibitors
Tamaoki, T. (1991) · Methods in Enzymology · doi:10.1016/0076-6879(91)01030-6 · Cited by 330
The Prognostic Significance of Altered Cyclin-Dependent Kinase Inhibitors in Human Cancer
Tsihlias, M., Kapusta, M., & Slingerland, M. (1999) · Annual Review of Medicine · doi:10.1146/annurev.med.50.1.401 · Cited by 319
Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
Chen, Y.-N. P., Sharma, S. K., Ramsey, T. M., Jiang, L., Martin, M. S., Baker, K., Adams, P. D., Bair, K. W., & Kaelin, W. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4325 · Cited by 314
Cyclins, Cyclin-Dependent Kinases and Cdk Inhibitors: Implications in Cell Cycle Control and Cancer
MacLachlan, T. K., Sang, N., & Giordano, A. (1995) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v5.i2.20 · Cited by 309
Carlson, B., Lahusen, T. J., Singh, S., Loaiza‐Perez, A., Worland, P. J., Pestell, R. G., Albanese, C., Sausville, E. A., & Senderowicz, A. M. (1999) · PubMed · Cited by 287
Self-citationByrd, J. C., Shinn, C., Waselenko, J. K., Fuchs, E. J., Lehman, T. A., Nguyen, P. L., Flinn, I. W., Diehl, L. F., Sausville, E., & Grever, M. R. (1998) · Blood · doi:10.1182/blood.v92.10.3804 · Cited by 283
Schulze‐Gahmen, U., Brandsen, J., Jones, H. D., Morgan, D. O., Meijer, L., Vesely, J., & Kim, S. (1995) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340220408 · Cited by 279
Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy
Sedlacek, H., Czech, J., Naik, R., Kaur, G., Worland, P., Losiewicz, M., Parker, B., Carlson, B., Smith, A., Senderowicz, A., et al. (1996) · International Journal of Oncology · doi:10.3892/ijo.9.6.1143 · Cited by 275
Self-citationPark, D. S., Morris, E. J., Greene, L. A., & Geller, H. M. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-04-01256.1997 · Cited by 270
Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis.
Gansauge, S., Gansauge, F., Ramadani, M., Stobbe, H., Rau, B., Harada, N., & Beger, H. G. (1997) · PubMed · Cited by 261
Bible, K. C., & Kaufmann, S. H. (1997) · PubMed · Cited by 258
Tassan, J. P., Schultz, S. J., Bartek, J., & Nigg, E. A. (1994) · The Journal of cell biology · doi:10.1083/jcb.127.2.467 · Cited by 251
Park, D. S., Farinelli, S. E., & Greene, L. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.14.8161 · Cited by 250
Patel, V, Senderowicz, A. M., Pinto, D., Igishi, T., Raffeld, M., Quintanilla-Martinez, L., Ensley, J. F., Sausville, E. A., & Gutkind, J. S. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3661 · Cited by 246
Self-citationArguello, F., Alexander, M., Sterry, J. A., Tudor, G., Smith, E. M., Kalavar, N. T., Greene, J. F., Koss, W., Morgan, C. D., Stinson, S. F., et al. (1998) · PubMed · doi:10.1182/blood.v91.7.2482 · Cited by 240
(1997) · PubMed · Cited by 238
In vivo gene therapy with p53 or p21 adenovirus for prostate cancer.
Ja, E., Hall, S. J., Sehgal, I., Wang, J., Timme, T. L., Yang, G., Connell‐Crowley, L., Elledge, S. J., Ww, Z., & Harper, J. W. (1995) · PubMed · Cited by 236
Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death
Sandig, V., Brand, K., Herwig, S., Lukas, J., Bartek, J., & Strauss, M. (1997) · Nature Medicine · doi:10.1038/nm0397-313 · Cited by 234
Suppression of Apoptosis by Dominant Negative Mutants of Cyclin-dependent Protein Kinases
Meikrantz, W., & Schlegel, R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.17.10205 · Cited by 234
Graña, X., De Luca, A., Sang, N., Fu, Y., Claudio, P. P., Rosenblatt, J., Morgan, D. O., & Giordano, A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3834 · Cited by 231
Fuse, E., Tanii, H., Kurata, N., Kobayashi, H., Shimada, Y., Tamura, T., Sasaki, Y., Tanigawara, Y., Lush, R. D., Headlee, D. J., et al. (1998) · PubMed · Cited by 229
Self-citationZaharevitz, D. W., Gussio, R., Leost, M., Senderowicz, A. M., Lahusen, T. J., Kunick, C., Meijer, L., & Sausville, E. A. (1999) · PubMed · Cited by 225
Self-citation(1996) · PubMed · Cited by 221
p27Kip1 overexpression causes apoptotic death of mammalian cells
Wang, X., Gorospe, M., Huang, Y., & Holbrook, N. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201450 · Cited by 221
Gervais, J. L. M., Seth, P., & Zhang, H. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.30.19207 · Cited by 212
König, A., Schwartz, G. K., Mohammad, R. M., Al-Katib, A., & Gabrilove, J. L. (1997) · Blood · doi:10.1182/blood.v90.11.4307 · Cited by 191
Bible, K. C., & Kaufmann, S. H. (1996) · PubMed · Cited by 189
Akinaga, S., Gomi, K., Morimoto, M., Tamaoki, T., & Okabe, M. (1991) · PubMed · Cited by 189
UCN-01, a selective inhibitor of protein kinase C from Streptomyces.
TAKAHASHI, I., KOBAYASHI, E., ASANO, K., YOSHIDA, M., & NAKANO, H. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.1782 · Cited by 186
Craig, C., Wersto, R., Kim, M., Ohri, E., Li, Z., Katayose, D., Lee, S. J., Trepel, J., Cowan, K., & Seth, P. (1997) · Oncogene · doi:10.1038/sj.onc.1201064 · Cited by 182
Jin, X., Nguyen, D. M., Zhang, W. W., Kyritsis, A. P., & Roth, J. A. (1995) · PubMed · Cited by 179
Niculescu, A. B., Chen, X., Smeets, M. F. M. A., Hengst, L., Prives, C. L., & Reed, S. I. (1998) · Molecular and Cellular Biology · Cited by 177
Cell cycle arrest and DNA endoreduplication following p21Waf1/Cip1 expression
Bates, S., Ryan, K. M., Phillips, A. C., & Vousden, K. H. (1998) · Oncogene · doi:10.1038/sj.onc.1202104 · Cited by 176
Cyclins and Cyclin-Dependent Kinases: Theme and Variations
(1995) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60254-7 · Cited by 172
Ball, K. L., Laín, S., Fåhræus, R., Smythe, C., & Lane, D. P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00029-7 · Cited by 171
Fåhraeus, R., Paramio, J. M., Ball, K. L., Laín, S., & Lane, D. P. (1996) · Current Biology · doi:10.1016/s0960-9822(02)00425-6 · Cited by 170
The role of RB in cell cycle control
Hatakeyama, M., & Weinberg, R. A. (1995) · Progress in Cell Cycle Research · doi:10.1007/978-1-4615-1809-9_2 · Cited by 164
Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II.
Rickert, P., Seghezzi, W., Shanahan, F., Cho, H. K., & Lees, E. M. (1996) · PubMed · Cited by 160
Lee, S. J., Ha, M. J., Lee, J., Nguyen, P., Choi, Y. H., Pirnia, F., Kang, W.-K., Wang, X.-F., Kim, S.-J., & Trepel, J. B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.17.10618 · Cited by 160
TAKAHASHI, I., Saitoh, Y., Yoshida, M., Sano, H., Nakano, H., Morimoto, M., & Tamaoki, T. (1989) · The Journal of Antibiotics · doi:10.7164/antibiotics.42.571 · Cited by 158
Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue.
Seynaeve, C., Kazanietz, M. G., Blumberg, P. M., Sausville, E. A., & Worland, P. J. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10590-7 · Cited by 158
Kornmann, M., Arber, N., & Korc, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1323 · Cited by 155
Zhou, B.-B., Li, H., Yuan, J., & Kirschner, M. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6785 · Cited by 155
Akiyama, T., Yoshida, T., Tsujita, T., Shimizu, M., Mizukami, T., Okabe, M., & Akinaga, S. (1997) · PubMed · Cited by 152
Watts, C. K. W., Sweeney, K. J. E., Warlters, A., Musgrove, E. A., & Sutherland, R. L. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00689680 · Cited by 147
Chemical inhibitors of cyclin-dependent kinases
Meijer, L., & Kim, S. (1997) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(97)83011-x · Cited by 145
CVT-313, a Specific and Potent Inhibitor of CDK2 That Prevents Neointimal Proliferation
Brooks, E. E., Gray, N. S., Joly, A. H., Kerwar, S. S., Lum, R. T., Mackman, R. L., Norman, T., Rosete, J., Rowe, M. W., Schow, S. R., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.46.29207 · Cited by 143
Melillo, G., Sausville, E. A., Cloud, K., Lahusen, T. J., Varesio, L., & Senderowicz, A. M. (1999) · PubMed · Cited by 142
Self-citationWorland, P. J., Kaur, G., Stetler‐Stevenson, M., Sebers, S., Sartor, O. A., & Sausville, E. A. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90590-s · Cited by 141
Wang, Q., Worland, P. J., Clark, J. L., Carlson, B. A., & Sausville, E. A. (1995) · PubMed · Cited by 136
Seynaeve, C., Stetler‐Stevenson, M., Sebers, S., Kaur, G., Sausville, E. A., & Worland, P. J. (1993) · PubMed · Cited by 132
Cyclic activation of histone H1 kinase during sea urchin egg mitotic divisions
Meijer, L., & Pondaven, P. (1988) · Experimental Cell Research · doi:10.1016/0014-4827(88)90147-4 · Cited by 125
Human and Yeast Cdk-activating Kinases (CAKs) Display Distinct Substrate Specificities
Kaldis, P., Russo, A. A., Chou, H. S., Pavletich, N. P., & Solomon, M. J. (1998) · Molecular Biology of the Cell · doi:10.1091/mbc.9.9.2545 · Cited by 125
Kawakami, K., Futami, H., Takahara, J., & Yamaguchi, K. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.0310 · Cited by 120
Akinaga, S., Nomura, K., Gomi, K., & Okabe, M. (1993) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685833 · Cited by 118
Cyclin-Dependent KinasesInitial Approaches to Exploit a Novel Therapeutic Target
Sausville, E. A., Zaharevitz, D. W., Gussio, R., Meijer, L., Leost, M., Kunick, C., Schultz, R. J., Lahusen, T. J., Headlee, D. J., & Stinson, S. F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00062-x · Cited by 117
Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro
Chintala, S. K., Fueyo-Margareto, J., Gomez‐Manzano, C., Venkaiah, B., Bjerkvig, R., Yung, W. A., Sawaya, R. A., Kyritsis, A. P., & Rao, J. S. (1997) · Oncogene · doi:10.1038/sj.onc.1201382 · Cited by 108
TAKAHASHI, I., Asano, K., Kawamoto, I., Tamaoki, T., & Nakano, H. (1989) · The Journal of Antibiotics · doi:10.7164/antibiotics.42.564 · Cited by 107
Yu, L., Orlandi, L., Wang, P., Orr, M. S., Senderowicz, A. M., Sausville, E. A., Silvestrini, R., Watanabe, N., Piwnica-Worms, H. M., & O'Connor, P. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.50.33455 · Cited by 103
Self-citationEdwards, M. C., Wong, C., & Elledge, S. J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.4291 · Cited by 102
Clinical trials referral resource.
Cheson, B. D., Abrams, J., McCabe, M. S., & Crosson, K. (1990) · PubMed · Cited by 94
Akinaga, S., Nomura, K., Gomi, K., & Okabe, M. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685899 · Cited by 91
Roberge, M., Berlinck, R. G. S., Xu, L., Anderson, H. J., Lim, L. Y., Curman, D., Stringer, C. M., Friend, S. H., Davies, P., Vincent, I. J., et al. (1998) · PubMed · Cited by 91
Inhibition of cyclin D expression in human breast carcinoma cells by retinoids in vitro
Zhou, Q. Y., Stetler‐Stevenson, M., & Steeg, P. S. (1997) · Oncogene · doi:10.1038/sj.onc.1201142 · Cited by 90
Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models
Sausville, E. A., Lush, R. D., Headlee, D. J., Smith, A. C., Figg, W. D., Arbuck, S. G., Senderowicz, A. M., Fuse, E., Tanii, H., Kuwabara, T., et al. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051080 · Cited by 88
Self-citationGray-Bablin, J., Rao, S., & Keyomarsi, K. (1997) · PubMed · Cited by 87
Cell Cycle and Cancer: Critical Events at the G1 Restriction Point
Sal, G. D., Loda, M. F., & Pagano, M. (1996) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v7.i1-2.80 · Cited by 86
p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth.
Bonfanti, M., Taverna, S., Salmona, M., D’Incalci, M., & Broggini, M. (1997) · PubMed · Cited by 85
Hsueh, C.-T., Kelsen, D. P., & Schwartz, G. K. (1998) · PubMed · Cited by 81
Pollack, I. F., Kawecki, S., & Lazo, J. S. (1996) · Journal of neurosurgery · doi:10.3171/jns.1996.84.6.1024 · Cited by 73
Bunch, R., & Eastman, A. R. (1997) · PubMed · Cited by 73
Jäger, W. R., Zembsch, B., Wolschann, P., Pittenauer, E., Senderowicz, A. M., Sausville, E. A., Sedlacek, H. H., Graf, J., & Thalhammer, T. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00152-0 · Cited by 72
Self-citationRosania, G. R., Merlie, J. P., Gray, N. S., Chang, Y., Schultz, P. G., & Heald, R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4797 · Cited by 71
Rialet, V., & Meijer, L. (1991) · PubMed · Cited by 65
Husain, A., Yan, X., Rosales, N., Aghajanian, C. A., Schwartz, G. K., & Spriggs, D. R. (1997) · PubMed · Cited by 56
Cyclin D1antisense RNA destabilizes pRb and retards lung cancer cell growth
Driscoll, B., Wu, L., Buckley, S., Hall, F. L., Anderson, K. D., & Warburton, D. (1997) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1997.273.5.l941 · Cited by 55
Lee, H. R., Chang, T. H., Tebalt, M. J., Senderowicz, A. M., & Szabo, E. M. (1999) · International Journal of Oncology · doi:10.3892/ijo.15.1.161 · Cited by 45
Self-citationControl of eukaryotic cell cycle progression by phosphorylation of cyclin-dependent kinases.
Morgan, D. O., Fisher, R. P., Espinoza, F. H., Farrell, A., Nourse, J. L., Chamberlin, H., & Jin, P. (1998) · PubMed · Cited by 43
Tsuchida, E., & Urano, M. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)00549-x · Cited by 38
Clinical trials referral resource. Clinical trials of flavopiridol.
Wright, J., Blatner, G. L., & Cheson, B. D. (1998) · PubMed · Cited by 30
Buquet-Fagot, C., Lallemand, F., Montagne, M., & Mešter, J. (1997) · Anti-Cancer Drugs · doi:10.1097/00001813-199707000-00011 · Cited by 27
Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01
Kurata, N., Kuwabara, T., Tanii, H., Fuse, E., Akiyama, T., Akinaga, S., Kobayashi, H., Yamaguchi, K., & Kobayashi, S. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050939 · Cited by 24
Courage, C., Bradder, S. M., Jones, T., Schultze‐Mosgau, M., & Gescher, A. J. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971127)73:5<763::aid-ijc25>3.0.co;2-5 · Cited by 21
Cited by
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer
Vermeulen, K., Van Bockstaele, D. R., & Berneman, Z. N. (2003) · Cell Proliferation · doi:10.1046/j.1365-2184.2003.00266.x · Cited by 1,773
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
Weissleder, R., & Mahmood, U. (2001) · Radiology · doi:10.1148/radiology.219.2.r01ma19316 · Cited by 1,315
Protein Kinase Inhibitors: Insights into Drug Design from Structure
Noble, M. E. M., Endicott, J. A., & Johnson, L. N. (2004) · Science · doi:10.1126/science.1095920 · Cited by 1,198
Role of cell cycle in mediating sensitivity to radiotherapy
Pawlik, T. M., & Keyomarsi, K. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.03.005 · Cited by 1,102
Metadata
- Authors
- Senderowicz, A. M.
- Venue
- Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-03-01
- Volume
- 92
- Issue
- 5
- Pages
- 376-387
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2162517036
- Cited by
- 492
- References
- 113
- FWCI
- 21.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.